| Original language | English (US) |
|---|---|
| Article number | e000983 |
| Journal | BMJ Open Ophthalmology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Aug 1 2022 |
Keywords
- Clinical Trial
- Macula
- Treatment Medical
- Macular Edema/drug therapy
- Humans
- Endothelial Growth Factors
- Ranibizumab/therapeutic use
- Diabetes Mellitus
- Diabetic Retinopathy/drug therapy
ASJC Scopus subject areas
- Ophthalmology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: BMJ Open Ophthalmology, Vol. 7, No. 1, e000983, 01.08.2022.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision
T2 - Protocol V results in context
AU - Do, Diana V.
AU - Moini, Hadi
AU - Wykoff, Charles C.
N1 - Funding Information: This study was funded by Regeneron Pharmaceuticals, Inc. Funding Information: DVD reports serving as a consultant for Allergan, Asclepix, Boehringer Ingelheim, Clearside, Genentech, Kodiak Sciences and Regeneron Pharmaceuticals, Inc.; and receiving research funding from Asclepix, Boehringer Ingelheim, Genentech and Regeneron Pharmaceuticals, Inc. HM is an employee and shareholder of Regeneron Pharmaceuticals, Inc. CCW reports serving as a consultant for Acucela, Adverum, Aerpio, Alcon, Alimera Sciences, Allergan, Alnylam, Apellis, Arctic Vision, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies, Clearside Biomedical, Corcept Therapeutics, DORC, EyePoint, Genentech, Gyroscope, IVERIC Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Notal Vision, Novartis, OccuRx, ONL Therapeutics, Opthea, Oxurion, Palatin, Polyphotonix, Recens Medical, Regeneron Pharmaceuticals, Inc., RegenXBio, Roche, Santen, Takeda, Thea Open Innovation and Verana Health; receiving grants for research support from Adverum, Aerie Pharmaceuticals, Aldeyra, Allergan, Apellis, Boehringer Ingelheim, Chengdu Kanghong Biotechnologies, Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, IVERIC Bio, Kodiak Sciences, LMRI, Mylan, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron Pharmaceuticals, Inc., RegenXBio, Roche, Samsung Bioepis, Santen, Senju, Taiwan Liposome Company, and Xbrane BioPharma; and receiving speaker fees for speaker’s bureau from Regeneron Pharmaceuticals, Inc.
PY - 2022/8/1
Y1 - 2022/8/1
KW - Clinical Trial
KW - Macula
KW - Treatment Medical
KW - Macular Edema/drug therapy
KW - Humans
KW - Endothelial Growth Factors
KW - Ranibizumab/therapeutic use
KW - Diabetes Mellitus
KW - Diabetic Retinopathy/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85135928777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135928777&partnerID=8YFLogxK
U2 - 10.1136/bmjophth-2022-000983
DO - 10.1136/bmjophth-2022-000983
M3 - Article
C2 - 36161828
AN - SCOPUS:85135928777
SN - 2397-3269
VL - 7
JO - BMJ Open Ophthalmology
JF - BMJ Open Ophthalmology
IS - 1
M1 - e000983
ER -